亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

A composition and related anti-viral uses thereof

总结: our formulation is on the market with the trademark NOVIR. Trademark is registered on my name, Erdal Can Alkoclar as the 16 patents which currently protects our intellectual property rights. This product is an effective anti-viral treatment specially formulated for influenza but may possess required properties sufficient to become a candidate as an adjunctive treatment for AiDS and viral origined cancers. About 450-500 million people worldwide suffers from flu and other viral ailments.NOVIR has the simultenaous ability to suppress DNA polymerase, ribonucleotide reductase and reverse transcriptase via rapid and simultenaous upregulation of tissue spesific cAMP and cGMP expression which leads to the potent suppression of above mentioned viral enzmyes. At the same time NOVIR has the ability to suppress pro-inflammatory cytokines such as TNF-A, cox-2, pge-2 and nf-kappaB expressions thus providing a double route treatment for both the cause and symptoms of viral infections.

附加资料: Patent Number: US8710248B2
Application Number: US13416657A
Inventor: Chan, Tak-Hang | Lam, Wai-Har | Chow, Larry Ming-Cheung | Dou, Qing Ping | Kuhn, Deborah Joyce | Kazi, Aslamuzzaman | Wan, Sheng Biao | Landis-Piwowar, Kristin R.
Priority Date: 19 Aug 2004
Priority Number: US8710248B2
Application Date: 9 Mar 2012
Publication Date: 29 Apr 2014
IPC Current: C07D031100 | A61K003125
US Class: 549399 | 514456
Assignee Applicant: The Hong Kong Polytechnic University
Title: (−)-epigallocatechin gallate derivatives for inhibiting proteasome | (−)-epigallocatechin gallate derivatives for inhibiting proteasome
Usefulness: (−)-epigallocatechin gallate derivatives for inhibiting proteasome | (−)-epigallocatechin gallate derivatives for inhibiting proteasome
Summary: Compounds (I) are used as medicaments to reduce tumor cell growth (claimed). Treated breast cancer (MCF-7) cells were treated with compounds (I) for 24 hours, followed by MTT analysis to determine their effects on cell proliferation. Compound (2S,3R)-trans-5,7-bis(acetyloxy)-2-[3,4,5-tris(acetyloxy)phenyl]chroman-3-yl-3-(acetyloxy)benzoate caused 70% inhibition at 25 μM.
Novelty: New chromanyl ester derivatives, are proteasome inhibitors used to reduce tumor cell growth

欲了解更多信息，请点击这里